
![]()
The Speakers are :
Hasbullah Thabrany
Center for Health Economics and Policy
School of Public Health, Universitas Indonesia
Kampus UI, Depok 16424
Fax +62 21 8087 1616
Joseph E. Biskupiak, PhD, MBA
Research Associate Professor
Associate Director, PORC
Department of Pharmacotherapy, University of Utah, SLC, Utah.
Joseph.biskupiak@hsc.utah.edu

Alan Haycox BA MA PhD
Reader in Health Economics
University of Liverpool Management School, UK
A.R.Haycox@liverpool.ac.uk
Zoltán Kaló, MD, MSc, PhD
Director, Health Economics
Research Centre, Faculty of Social
Sciences, Eötvös Loránd
University, Budapest
kalo@tatk.elte.hu

Abdulkadir Keskinaslan, MD, MBA, MPH
Market Pricing Director ASIA
Global Pricing & Reimbursement
Novartis Pharma AG
CH-4002 Basel, Switzerland
abdulkadir.keskinaslan@novartis.com
Prof. Rob Carter
Chair in Health & Human Serv. Econ. School of
Health & Social Development
Deakin University, Australia. rob.
carter@deakin.edu.au
ABOUT NOVARTIS
On March 7th, 1996 Sandoz and Ciba-Geigy, the two Swiss-based chemical/life sciences giants, became Novartis.